Nippon Life Global Investors Americas Inc. Buys 12,030 Shares of Johnson & Johnson (JNJ)

Nippon Life Global Investors Americas Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 168,006 shares of the company’s stock after purchasing an additional 12,030 shares during the quarter. Johnson & Johnson makes up approximately 1.9% of Nippon Life Global Investors Americas Inc.’s portfolio, making the stock its 10th largest position. Nippon Life Global Investors Americas Inc.’s holdings in Johnson & Johnson were worth $21,681,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Appleton Partners Inc. MA raised its position in Johnson & Johnson by 4.4% during the fourth quarter. Appleton Partners Inc. MA now owns 72,170 shares of the company’s stock valued at $9,313,000 after acquiring an additional 3,021 shares in the last quarter. Polaris Greystone Financial Group LLC raised its position in Johnson & Johnson by 29.8% during the fourth quarter. Polaris Greystone Financial Group LLC now owns 5,718 shares of the company’s stock valued at $738,000 after acquiring an additional 1,313 shares in the last quarter. Howard Capital Management raised its position in Johnson & Johnson by 0.4% during the fourth quarter. Howard Capital Management now owns 106,510 shares of the company’s stock valued at $13,745,000 after acquiring an additional 392 shares in the last quarter. Advisors Capital Management LLC raised its position in Johnson & Johnson by 7.4% during the fourth quarter. Advisors Capital Management LLC now owns 118,763 shares of the company’s stock valued at $15,326,000 after acquiring an additional 8,195 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Johnson & Johnson by 4.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,051,631 shares of the company’s stock valued at $135,713,000 after acquiring an additional 43,691 shares in the last quarter. Institutional investors and hedge funds own 67.32% of the company’s stock.

Several equities analysts recently weighed in on JNJ shares. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Citigroup cut their price objective on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 2nd. Wells Fargo & Co reaffirmed an “outperform” rating and set a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Barclays reaffirmed an “equal weight” rating and set a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Finally, Morgan Stanley set a $140.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Thursday, December 20th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $143.58.

NYSE:JNJ opened at $138.02 on Wednesday. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.99. The company has a market capitalization of $366.27 billion, a PE ratio of 16.87, a PEG ratio of 2.08 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company had revenue of $20.02 billion for the quarter, compared to analyst estimates of $19.55 billion. During the same quarter last year, the firm posted $2.06 earnings per share. The company’s quarterly revenue was up .1% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 8.58 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Nippon Life Global Investors Americas Inc. Buys 12,030 Shares of Johnson & Johnson (JNJ)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2019/04/17/nippon-life-global-investors-americas-inc-buys-12030-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Key terms to understand channel trading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit